tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Perseus Proteomics’ PPMX-T003 Gains Support for Orphan Drug Development

Story Highlights
Perseus Proteomics’ PPMX-T003 Gains Support for Orphan Drug Development

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Perseus Proteomics, Inc. ( (JP:4882) ) has issued an update.

Perseus Proteomics Inc. announced that its drug candidate, PPMX-T003, intended for treating aggressive NK cell leukemia, has been selected for the Drug Discovery Support Program for Orphan drugs by Japan’s AMED. This selection supports the ongoing clinical trials, which have been extended by a year, and provides a subsidy of 100 million yen to aid in trial expenses, potentially impacting the company’s financial forecast for FY2026/3.

More about Perseus Proteomics, Inc.

Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the research and development of therapeutic drugs. The company specializes in creating treatments for rare diseases, with a particular emphasis on orphan drugs, which are medications for conditions affecting a small percentage of the population.

YTD Price Performance: 16.37%

Average Trading Volume: 792,805

Technical Sentiment Consensus Rating: Sell

Current Market Cap: Yen9.64B

For an in-depth examination of 4882 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1